[The use of recombinant human B-type natriuretic peptide for the protection of cardiac and renal functions in heart failure patients with acute anterior myocardial infarction in peri-operative period of primary percutaneous coronary intervention]

What Was Tested

This randomized controlled trial paper looks at BNP (Nesiritide).

To evaluate the protective effect of recombinant human B-type natriuretic peptide (rhBNP) on cardiac and renal functions in heart failure (HF) patients as a result of acute anterior myocardial infarction (AAMI) in peri-operative period of primary percutaneous coronary intervention (pPCI).

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

One hundred and twenty-six patients with AAMI-HF were enrolled into this study.

All patients undertaken pPCI were randomly assigned to the rhBNP group (n=62) or the control group (n=64). rhBNP or nitroglycerin was intravenously administered on the basis of conventional treatment from first day of admission to 24 hours after pPCI in both groups.

How the Study Was Run

The researchers set it up as a randomized study.

The participants were allocated by chance, so the BNP (Nesiritide) group and the comparison group should start out alike.

The methods mention a period of 30 days.

Heart rate (HR), systolic blood pressure (SBP), B-type natriuretic peptide (BNP), estimated glomerular filtration rate (eGFR) and heart function were observed.

All patients were followed up for 30 days for the observation of main adverse cardiac events (MACE).

What Was Measured

Topics PubMed links to this paper include Angioplasty, Balloon, Coronary, Anterior Wall Myocardial Infarction, Electrocardiography, Heart Failure, Kidney Function Tests, Natriuretic Peptide, Brain and Prognosis.

What This Means in Plain Language

The paper is a randomized study of BNP (Nesiritide) over 30 days.

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue), a journal based in China.

More context: the BNP (Nesiritide) compound page, all human trials.